All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

September 6, 2019

Federal Court Enters into Consent Decree with Tennessee Distributors

Author(s):

Pharmaceutical Technology Editors

A US District Court judge in Tennessee entered a consent decree of permanent injunction against Basic Reset and Biogenyx after multiple FDA inspections of the companies’ facility found violations of the Federal Food, Drug, and Cosmetic Act.

FDA announced on Sept. 3, 2019 that a US District Court Judge in Tennessee entered into a consent decree of permanent injunction against Basic Reset and Biogenyx, sole proprietorships, Fred R. Kaufman III, owner, and Kimberly Kaufman, after multiple FDA inspections of the companies’ facility found violations of the Federal Food, Drug, and Cosmetic Act. The company is accused of having unlawfully distributed unapproved new drugs, adulterated and misbranded dietary supplements, and an adulterated and misbranded device.

According to FDA, the agency has not approved the companies’ drugs or devices for uses claimed by the companies. During a facility inspection, FDA found violations of current good manufacturing practices (CGMPs) that included a failure to establish specifications for ensuring the identification of products received for labeling and a failure to investigate product complaints. FDA previously issued a warning letter for similar violations.

“Despite previous warnings, Basic Reset and Biogenyx placed consumers at risk by distributing certain products in violation of current good manufacturing practice (CGMP) requirements and products which failed to adequately meet labeling standards. The U.S. Food and Drug Administration remains fully committed to taking enforcement action against companies and owners who place unsuspecting American consumers at risk,” FDA Commissioner Ned Sharpless, MD, said in a statement.

Basic Reset and Biogenyx are prohibited from “directly or indirectly receiving, labeling, holding, or distributing dietary supplements, drugs, or devices at or from their facility until they take certain steps to ensure that all of these products comply with the law including, among other things, recalling their drugs, dietary supplements and device products, hiring qualified experts to ensure conformity with CGMP and other requirements and receiving written permission from the FDA to resume operations,” FDA said in a statement.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Dave Miller, PhD, Chief Scientific Officer, AustinPx
Related Content
Advertisement
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 16th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 16th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic. The virus is made up of purple pills. | Image Credit: © lunarts_studio - stock.adobe.com
August 16th 2025

BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial After mRNA Rollback

Patrick Lavery
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 16th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
Related Content
Advertisement
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

In Europe, the Use of Titanium Dioxide in Drugs Will Continue

Susan Haigney
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 16th 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 16th 2025

FDA Commissioner Applauds Florida Restriction on 7-OH Opioids

Susan Haigney
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
August 16th 2025

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
Coronavirus 2019-nCov novel coronavirus concept resposible for asian flu outbreak and coronaviruses influenza as dangerous flu strain cases as a pandemic. The virus is made up of purple pills. | Image Credit: © lunarts_studio - stock.adobe.com
August 16th 2025

BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial After mRNA Rollback

Patrick Lavery
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
August 16th 2025

Nxera’s New GLP-1 and GPCR-Targeted Drug Programs Aim to Advance Obesity and Metabolic Disorder Therapies

Feliza Mirasol
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.